

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
18 August 2022 (18.08.2022)



(10) International Publication Number
WO 2022/171853 A1

(51) International Patent Classification:

A61K 48/00 (2006.01) A61P 35/00 (2006.01)
A61K 38/17 (2006.01) C07K 14/715 (2006.01)
A61K 38/20 (2006.01)

(21) International Application Number:

PCT/EP2022/053477

(22) International Filing Date:

14 February 2022 (14.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2102049.0 13 February 2021 (13.02.2021) GB

(71) Applicant: PSIOXUS THERAPEUTICS LIMITED

[GB/GB]; PsiOxus House 4 - 10 The Quadrant, Barton Lane, Abingdon Oxfordshire OX14 3YS (GB).

(72) Inventors: CHAMPION, Brian Robert; c/o PsiOxus

Therapeutics Limited, PsiOxus House 4 - 10 The Quadrant, Barton Lane, Abingdon Oxfordshire OX14 3YS (GB).
ZONCA, Manuela; c/o PsiOxus Therapeutics Limited, PsiOxus House 4 - 10 The Quadrant, Barton Lane, Abingdon Oxfordshire OX14 3YS (GB).

(74) Agent: STERLING IP LTD; Orion House Bessemer

Road, Welwyn Garden City Hertfordshire AL7 1HH (GB).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ADENOVIRUS ENCODING IL-15

Figure 2A



(57) Abstract: A group B adenovirus comprising a sequence of formula 5'ITR-B₁-B_A-B₂-B_X-B_B-B_Y-B₃-3'ITR, wherein: B_Y comprises a sequence -G1-G2_n-G3_m-G4_p-G5_q. G1 is a first transgene. G2 is a second transgene. G3 is a third transgene. G4 is a fourth transgene. G5 is a fifth transgene and IL-15 is encoded as a transgene in at least one of said locations, and characterised in that B_Y also encodes a polypeptide comprising the sushi domain of IL-15R alpha.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*